[1] IDF, IDF DIABETES ATLAS 9th edition 2019. 2019.
[2] WHO, Global report on diabetes. 2018.
[3] M. H. Forouzanfar, L. Alexander, V. F. Bachman, S. Biryukov, M. Brauer, D. Casey, M. M. Coates, K. Delwiche, K. Estep, J. J. Frostad, K. C. Astha, H. H. Kyu, M. Moradi- Lakeh, M. Ng, E. Slepak, B. A. Thomas, J. Wagner, T. Achoki, C. Atkinson, et al., “Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013,” Lancet, 386(10010), 2287–2323, 2015.
[4] J. Fernández-Tajes, K. J. Gaulton, M. Van De Bunt, J. Torres, M. Thurner, A. Mahajan, A. L. Gloyn, K. Lage, and M. I. McCarthy, “Developing a network view of type 2 diabetes risk pathways through integration of genetic, genomic and functional data,” Genome Med., 11(1), 1–14, 2019.
[5] X. Jing, J. Chen, Y. Dong, D. Han, H. Zhao, X. Wang, F. Gao, C. Li, Z. Cui, Y. Liu, and J. Ma, “Related factors of quality of life of type 2 diabetes patients: a systematic review and meta-analysis,” Health Qual. Life Outcomes, 16(1), 1–14, 2018.
[6] T. Y. Wong, C. M. G. Cheung, M. Larsen, S. Sharma, and R. Simó, “Diabetic retinopathy,” Nat. Rev. Dis. Prim., 2, 2016.
[7] K. Umanath and J. B. Lewis, “Update on Diabetic Nephropathy: Core Curriculum 2018,” Am. J. Kidney Dis., 71(6), 884–895, 2018.
[8] E. L. Feldman, B. C. Callaghan, R. Pop-Busui, D. W. Zochodne, D. E. Wright, D. L. Bennett, V. Bril, J. W. Russell, and V. Viswanathan, “Diabetic neuropathy,” Nat. Rev. Dis. Prim., 5(1), 2019.
[9] R. Madonna, D. Pieragostino, C. R. Balistreri, C. Rossi, Y. J. Geng, P. Del Boccio, and R. De Caterina, “Diabetic macroangiopathy: Pathogenetic insights and novel therapeutic approaches with focus on high glucose-mediated vascular damage,” Vascul. Pharmacol., 107, 27–34, 2018.
[10] G. S. Meneilly and D. M. Tessier, “Diabetes, Dementia and Hypoglycemia,” Can. J. Diabetes, 40(1), 73–76, 2016.
[11] D. Liccardo, A. Cannavo, G. Spagnuolo, N. Ferrara, A. Cittadini, C. Rengo, and G. Rengo, “Periodontal disease: A risk factor for diabetes and cardiovascular disease,” Int. J. Mol. Sci., 20(6), 2019.
[12] S. P. Fisher-Hoch, C. E. Mathews, and J. B. Mccormick, “Obesity, diabetes and pneumonia: The menacing interface of non-communicable and infectious diseases,” Trop. Med. Int. Heal., 18(12), 1510–1519, 2013.
[13] G. Shlomai, B. Neel, D. LeRoith, and E. J. Gallagher, “Type 2 diabetes mellitus and cancer: The role of pharmacotherapy,” J. Clin. Oncol., 34(35), 4261–4269, 2016.
[14] A. Berbudi, N. Rahmadika, A. I. Tjahjadi, and R. Ruslami, “Type 2 Diabetes and its Impact on the Immune System,” Curr. Diabetes Rev., 16(5), 442–449, 2020.
[15] S. Maeda, M. A. Kobayashi, S. I. Araki, T. Babazono, B. I. Freedman, M. A. Bostrom, J. N. Cooke, M. Toyoda, T. Umezono, L. Tarnow, T. Hansen, P. Gaede, A. Jorsal, D. P. K. Ng, M. Ikeda, T. Yanagimoto, T. Tsunoda, H. Unoki, K. Kawai, et al., “A single nucleotide polymorphism within the acetyl-coenzyme A carboxylase beta gene is associated with proteinuria in patients with type 2 diabetes,” PLoS Genet., 6(2), 2010.
[16] Centers for Disease Control and Prevention, “National Diabetes Prevention Program,” 2019. https://www.cdc.gov/diabetes/prevention/index.html.
[17] M. A. Felmlee, R. S. Jones, V. Rodriguez-Cruz, K. E. Follman, and M. E. Morris, “Monocarboxylate transporters (SLC16): Function, regulation, and role in health and disease,” Pharmacol. Rev., 72(2), 466–485, 2020.
[18] A. P. Halestrap, “The SLC16 gene family-Structure, role and regulation in health and disease,” Mol. Aspects Med., 34(2–3), 337–349, 2013.
[19] Y. Murakami, N. Kohyama, Y. Kobayashi, M. Ohbayashi, H. Ohtani, Y. Sawada, and T. Yamamoto, “Functional characterization of human monocarboxylate transporter 6 (SLC16A5),” Pharmacology, 33(12), 1845–1851, 2005.
[20] N. Kohyama, H. Shiokawa, M. Ohbayashi, Y. Kobayashi, and T. Yamamoto, “Characterization of monocarboxylate transporter 6: Expression in human intestine and transport of the antidiabetic drug nateglinide,” Drug Metab. Dispos., 41(11), 1883–1887, 2013.
[21] S. E. Hugo, L. Cruz-Garcia, S. Karanth, R. M. Anderson, D. Y. R. Stainier, and A. Schlegel, “A monocarboxylate transporter required for hepatocyte secretion of ketone bodies during fasting,” Genes Dev., 26(3), 282–293, 2012.
[22] R. S. Jones and M. E. Morris, “Monocarboxylate Transporters: Therapeutic Targets and Prognostic Factors in Disease,” Clin. Pharmacol. Ther., 100(5), 454–463, 2016.
[23] E. C. H. Friesema, S. Ganguly, A. Abdalla, J. E. Manning Fox, A. P. Halestrap, and T. J. Visser, “Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter,” J. Biol. Chem., 278(41), 40128–40135, 2003.
[24] E. C. H. Friesema, G. G. J. M. Kuiper, J. Jansen, T. J. Visser, and M. H. A. Kester, “Thyroid hormone transport by the human monocarboxylate transporter 8 and its rate- limiting role in intracellular metabolism,” Mol. Endocrinol., 20(11), 2761–2772, 2006.
[25] D. K. Kim, Y. Kanai, A. Chairoungdua, H. Matsuo, S. H. Cha, and H. Endou, “Expression Cloning of a Na+-independent Aromatic Amino Acid Transporter with Structural Similarity to H+/Monocarboxylate Transporters,” J. Biol. Chem., 276(20), 17221–17228, 2001.
[26] J. Abplanalp, E. Laczko, N. J. Philp, J. Neidhardt, J. Zuercher, P. Braun, D. F. Schorderet, F. L. Munier, F. Verrey, W. Berger, S. M. R. Camargo, and B. Kloeckener- Gruissem, “The cataract and glucosuria associated monocarboxylate transporter MCT12 is a new creatine transporter,” Hum. Mol. Genet., 22(16), 3218–3226, 2013.
[27] M. Takahashi, H. Kishimoto, Y. Shirasaka, and K. Inoue, “Functional characterization of monocarboxylate transporter 12 (SLC16A12/MCT12) as a facilitative creatine transporter,” Drug Metab. Pharmacokinet., 35(3), 281–287, 2020.
[28] P. Würtz, M. Tiainen, V. P. Mak̈inen, A. J. Kangas, P. Soininen, J. Saltevo, S. Keinan̈ en-Kiukaanniemi, P. Mäntyselkä, T. Lehtimak̈i, M. Laakso, A. Jula, M. Kähönen, M. Vanhala, and M. Ala-Korpela, “Circulating metabolite predictors of glycemia in middle- aged men and women,” Diabetes Care, 35(8), 1749–1756, 2012.
[29] S. O. Crawford, R. C. Hoogeveen, F. L. Brancati, B. C. Astor, C. M. Ballantyne, M. I. Schmidt, and J. H. Young, “Association of blood lactate with type 2 diabetes: The atherosclerosis risk in communities carotid MRI study,” Int. J. Epidemiol., 39(6), 1647– 1655, 2010.
[30] S. P. Juraschek, E. Selvin, E. R. Miller, F. L. Brancati, and J. H. Young, “Plasma lactate and diabetes risk in 8045 participants of the Atherosclerosis Risk in Communities Study,” Ann. Epidemiol., 23(12), 791-796.e4, 2013.
[31] T. Enoki, Y. Yoshida, H. Hatta, and A. Bonen, “Exercise training alleviates MCT1 and MCT4 reductions in heart and skeletal muscles of STZ-induced diabetic rats,” J. Appl. Physiol., 94(6), 2433–2438, 2003.
[32] S. Sasaki, Y. Futagi, M. Kobayashi, J. Ogura, and K. Iseki, “Functional characterization of 5-oxoproline transport via SLC16A1/MCT1,” J. Biol. Chem., 290(4), 2303–2311, 2015.
[33] I. Higuchi, Y. Kimura, M. Kobayashi, K. Narumi, A. Furugen, H. Miyoshi, A. Nakamura, T. Yamada, T. Atsumi, and K. Iseki, “Relationships between plasma lactate, plasma alanine, genetic variations in lactate transporters and type 2 diabetes in the Japanese population,” Drug Metab. Pharmacokinet., 35(1), 2019.
[34] A. L. Williams Amy, S. B. R. Jacobs Suzanne, H. Moreno-Macías, A. Huerta-Chagoya, C. Churchhouse, C. Márquez-Luna, M. J. Gómez-Vázquez, N. P. Burtt Noël, C. A. Aguilar- Salinas, C. González-Villalpando, J. C. Florez, L. Orozco, T. Tusié-Luna, D. Altshuler, S. Ripke, A. K. Manning, H. García-Ortíz, B. Neale, D. Reich, et al., “Sequence variants in SLC16A11 are a common risk factor for type 2 diabetes in Mexico,” Nature, 506(7486), 97–101, 2014.
[35] K. Hara, H. Fujita, T. A. Johnson, T. Yamauchi, K. Yasuda, M. Horikoshi, C. Peng, C. Hu, R. C. W. Ma, M. Imamura, M. Iwata, T. Tsunoda, T. Morizono, N. Shojima, W. Y. So, T. F. Leung, P. Kwan, R. Zhang, J. Wang, et al., “Genome-wide association study identifies three novel loci for type 2 diabetes.,” Hum. Mol. Genet., 23(1), 239–246, 2014.
[36] W. Kim, A. Deik, C. Gonzalez, M. E. Gonzalez, F. Fu, M. Ferrari, C. L. Churchhouse, J. C. Florez, S. B. R. Jacobs, C. B. Clish, and E. P. Rhee, “Polyunsaturated Fatty Acid Desaturation Is a Mechanism for Glycolytic NAD + Recycling,” Cell Metab., 29(4), 856- 870, 2019.
[37] V. Rusu, E. Hoch, J. M. Mercader, D. E. Tenen, M. Gymrek, C. R. Hartigan, M. DeRan, M. von Grotthuss, P. Fontanillas, A. Spooner, G. Guzman, A. A. Deik, K. A. Pierce, C. Dennis, C. B. Clish, S. A. Carr, B. K. Wagner, M. Schenone, M. C. Y. Ng, et al., “Type 2 Diabetes Variants Disrupt Function of SLC16A11 through Two Distinct Mechanisms,” Cell, 170(1), 199-212, 2017.
[38] Y. Zhao, Z. Feng, Y. Zhang, Y. Sun, Y. Chen, X. Liu, S. Li, T. Zhou, L. Chen, Y. Wei, D. Ma, K. O. Lui, H. Ying, Y. Chen, and Q. Ding, “Gain-of-Function Mutations of SLC16A11 Contribute to the Pathogenesis of Type 2 Diabetes,” Cell Rep., 26(4), 884-892, 2019.
[39] F. Fei, X. Guo, Y. Chen, X. Liu, J. Tu, J. Xing, Z. Chen, J. Ji, and X. He, “Polymorphisms of monocarboxylate transporter genes are associated with clinical outcomes in patients with colorectal cancer,” J. Cancer Res. Clin. Oncol., 141(6), 1095–1102, 2015.
[40] X. Guo, C. Chen, B. Liu, Y. Wu, Y. Chen, X. Zhou, X. Huang, X. Li, H. Yang, Z. Chen, and J. Xing, “Genetic variations in monocarboxylate transporter genes as predictors of clinical outcomes in non-small cell lung cancer,” Tumor Biol., 36(5), 3931–3939, 2015.
[41] O. N. Fedotovskaya, L. J. Mustafina, D. V. Popov, O. L. Vinogradova, and I. I. Ahmetov, “A common polymorphism of the MCT1 gene and athletic performance,” Int. J. Sports Physiol. Perform., 9(1), 173–180, 2014.
[42] M. Massidda, N. Eynon, V. Bachis, L. Corrias, C. Culigioni, F. Piras, P. Cugia, M. Scorcu, and C. M. Calò, “Influence of the MCT1 rs1049434 on Indirect Muscle Disorders/Injuries in Elite Football Players,” Sport. Med. - Open, 1(1), 33, 2015.
[43] P. M. van Hasselt, S. Ferdinandusse, G. R. Monroe, J. P. N. Ruiter, M. Turkenburg, M. J. Geerlings, K. Duran, M. Harakalova, B. van der Zwaag, A. A. Monavari, I. Okur, M. J. Sharrard, M. Cleary, N. O’Connell, V. Walker, M. E. Rubio-Gozalbo, M. C. de Vries, G. Visser, R. H. J. Houwen, et al., “Monocarboxylate Transporter 1 Deficiency and Ketone Utilization,” N. Engl. J. Med., 371(20), 1900–1907, 2014.
[44] T. Yamamoto, K. Shimojima, A. Umemura, M. Uematsu, T. Nakayama, and K. Inoue, “SLC16A2 mutations in two Japanese patients with Allan-Herndon-Dudley syndrome,” Hum. Genome Var., 1, 14–16, 2014.
[45] F. Novara, S. Groeneweg, E. Freri, M. Estienne, P. Reho, S. Matricardi, B. Castellotti, W. E. Visser, O. Zuffardi, and T. J. Visser, “Clinical and Molecular Characteristics of SLC16A2 (MCT8) Mutations in Three Families with the Allan–Herndon–Dudley Syndrome,” Hum. Mutat., 38(3), 260–264, 2017.
[46] W. Zhu, Y. Deng, and X. Zhou, “Multiple Membrane Transporters and Some Immune Regulatory Genes are Major Genetic Factors to Gout,” Open Rheumatol. J., 12(1), 94– 113, 2018.
[47] X. F. Huang, L. Sun, C. Zhang, Z. Zhou, H. Chen, L. Zhang, M. A. Brown, and X. Xia, “Whole-Exome Sequencing Reveals a Rare Missense Variant in SLC16A9 in a Pedigree with Early-Onset Gout,” Biomed Res. Int., 2020, 2020.
[48] B. Kloeckener-Gruissem, K. Vandekerckhove, G. Nürnberg, J. Neidhardt, C. Zeitz, P. Nürnberg, I. Schipper, and W. Berger, “Mutation of Solute Carrier SLC16A12 Associates with a Syndrome Combining Juvenile Cataract with Microcornea and Renal Glucosuria,” Am. J. Hum. Genet., 82(3), 772–779, 2008.
[49] M. Traurig, R. L. Hanson, A. Marinelarena, S. Kobes, P. Piaggi, S. Cole, J. E. Curran, J. Blangero, H. Göring, S. Kumar, R. G. Nelson, B. V. Howard, W. C. Knowler, L. J. Baier, and C. Bogardus, “Analysis of SLC16A11 variants in 12,811 American Indians: Genotype-obesity interaction for type 2 diabetes and an association with RNASEK expression,” Diabetes, 65(2), 510–519, 2016.
[50] C. B. Lean and E. J. D. Lee, “Genetic Variations in the MCT1 (SLC16A1) Gene in the Chinese Population of Singapore,” Drug Metab. Pharmacokinet., 24(5), 469–474, 2009.
[51] M. Asari, K. Okuda, C. Hoshina, T. Omura, Y. Tasaki, H. Shiono, K. Matsubara, and K. Shimizu, “Multicolor-based discrimination of 21 short tandem repeats and amelogenin using four fluorescent universal primers,” Anal. Biochem., 494, 16–22, 2016.
[52] The 1000 Genomes Project Consortium, “A map of human genome variation from population-scale sequencing,” Nature, 467(7319), 1061–1073, 2010.
[53] The 1000 Genomes Project Consortium, “An integrated map of structural variation in 2,504 human genomes,” Nature, 526(7571), 75–81, 2015.
[54] P. Almeda-Valdes, D. V. G. Velasco, O. A. Campos, O. Y. Bello-Chavolla, M. D. R. Sevilla-González, T. V. Ruiz, A. J. M. Rosado, C. J. Bautista, L. M. Hernandez, I. Cruz- Bautista, H. Moreno-Macias, A. Huerta-Chagoya, K. G. Rodríguez-Álvarez, G. A. Walford, S. B. R. Jacobs, L. E. G. Pineda, M. L. Ordoñez-Sánchez, E. Roldan-Valadez, J. Azpiroz, et al., “The SLC16A11 risk haplotype is associated with decreased insulin action, higher transaminases and large-size adipocytes,” Eur. J. Endocrinol., 180(2), 99– 107, 2019.
[55] Y. Kimura, M. Kobayashi, M. Asari, I. Higuchi, K. Narumi, A. Furugen, and K. Iseki, “Genetic variations in the monocarboxylate transporter genes (SLC16A1, SLC16A3, and SLC16A11) in the Japanese population,” Drug Metab. Pharmacokinet., 33(5), 215–218, 2018.
[56] 厚生労働省, “平成28年 国民健康・栄養調査結果の概要,” 2016.
[57] K. Yasuda, K. Miyake, Y. Horikawa, K. Hara, H. Osawa, H. Furuta, Y. Hirota, H. Mori, A. Jonsson, Y. Sato, K. Yamagata, Y. Hinokio, H. Y. Wang, T. Tanahashi, N. Nakamura, Y. Oka, N. Iwasaki, Y. Iwamoto, Y. Yamada, et al., “Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus,” Nat. Genet., 40(9), 1092–1097, 2008.
[58] M. Imamura, S. Maeda, T. Yamauchi, K. Hara, K. Yasuda, T. Morizono, A. Takahashi, M. Horikoshi, M. Nakamura, H. Fujita, T. Tsunoda, M. Kubo, H. Watada, H. Maegawa, M. Okada-Iwabu, M. Iwabu, N. Shojima, T. Ohshige, S. Omori, et al., “A single- nucleotide polymorphism in ANK1 is associated with susceptibility to type 2 diabetes in Japanese populations,” Hum. Mol. Genet., 21(13), 3042–3049, 2012.
[59] A. L. Miranda-Lora, M. Cruz, M. Molina-Díaz, J. Gutiérrez, S. Flores-Huerta, and M. Klünder-Klünder, “Associations of common variants in the SLC16A11, TCF7L2, and ABCA1 genes with pediatric-onset type 2 diabetes and related glycemic traits in families: A case-control and case-parent trio study,” Pediatr. Diabetes, 18(8), 824–831, 2017.
[60] A. Huerta-Chagoya, P. Vázquez-Cárdenas, H. Moreno-Macías, L. Tapia-Maruri, R. Rodríguez-Guillén, E. López-Vite, G. García-Escalante, F. Escobedo-Aguirre, A. Parra- Covarrubias, R. Cordero-Brieño, L. Manzo-Carrillo, R. Zacarías-Castillo, C. Vargas- García, C. Aguilar-Salinas, and T. Tusié-Luna, “Genetic determinants for gestational diabetes mellitus and related metabolic traits in Mexican women,” PLoS One, 10(5), 2015.
[61] Y. Zhang, D. Xu, H. Huang, S. Chen, L. Wang, L. Zhu, X. Jiang, X. Ruan, X. Luo, P. Cao, W. Liu, Y. Pan, Z. Wang, and Y. Chen, “Regulation of glucose homeostasis and lipid metabolism by PPP1R3G-mediated hepatic glycogenesis,” Mol. Endocrinol., 28(1), 116– 126, 2014.
[62] D. R. Matthews, J. R. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, R. C. Turner, and R. Infirmary, “Homeostasis model assessment: insulin resistance and beta- cell function from fasting plasma glucose and insulin concentrations in man,” Diabetologia, 28(7), 412–419, 1985.
[63] T. Zhang, Z. Qi, H. Wang, and S. Ding, “Adeno-Associated Virus-Mediated Knockdown of SLC16A11 Improves Glucose Tolerance and Hepatic Insulin Signaling in High Fat Diet- Fed Mice,” Exp. Clin. Endocrinol. Diabetes, 2019.
[64] A. San Martín, S. Ceballo, F. Baeza-Lehnert, R. Lerchundi, R. Valdebenito, Y. Contreras-Baeza, K. Alegría, and L. F. Barros, “Imaging mitochondrial flux in single cells with a FRET sensor for pyruvate,” PLoS One, 9(1), 2014.
[65] P. D. Velentzas, L. Zhang, G. Das, T. K. Chang, C. Nelson, W. R. Kobertz, and E. H. Baehrecke, “The Proton-Coupled Monocarboxylate Transporter Hermes Is Necessary for Autophagy during Cell Death,” Dev. Cell, 47(3), 281-293, 2018.
[66] J. Madrigal-Matute and A. M. Cuervo, “Regulation of Liver Metabolism by Autophagy,” Gastroenterology, 150(2), 328–339, 2016.
[67] T. Yamamuro, T. Kawabata, A. Fukuhara, S. Saita, S. Nakamura, H. Takeshita, M. Fujiwara, Y. Enokidani, G. Yoshida, K. Tabata, M. Hamasaki, A. Kuma, K. Yamamoto, I. Shimomura, and T. Yoshimori, “Age-dependent loss of adipose Rubicon promotes metabolic disorders via excess autophagy,” Nat. Commun., 11(1), 1–16, 2020.